Navigation Links
Neurocrine Biosciences Announces Successful Phase IIa Clinical Trial for VMAT2 Inhibitor
Date:4/5/2011

SAN DIEGO, April 5, 2011 /PRNewswire/ --Neurocrine Biosciences, Inc. (NASDAQ: NBIX) announced today that it has completed the dosing and preliminary assessment of the initial cohort of Tardive Dyskinesia patients using its proprietary Vesicular Monoamine Transporter 2 inhibitor (VMAT2), NBI-98854. Based on this data, the Company is initiating the Investigational New Drug (IND) application process with the U.S. Food and Drug Administration (FDA).

"We are very pleased with these preliminary results from our VMAT2 Phase IIa study," said Christopher F. O'Brien, Chief Medical Officer of Neurocrine Biosciences.  "Over the twelve days of treatment with our VMAT2 inhibitor, subjects showed a marked improvement in abnormal hyperkinetic movements. The drug was generally well tolerated and showed the desired pharmacokinetic profile previously demonstrated in two Phase I studies."

The open-label Phase IIa study was designed to assess efficacy, safety and tolerability of NBI-98854 in up to ten schizophrenia patients who have moderate to severe Tardive Dyskinesia over a twelve-day period. The impact on the dyskinesia was assessed utilizing the Abnormal Involuntary Movement Scale (AIMS). The dosing regimen consisted of three, four-day periods of NBI-98854 at increasing doses of 12.5mg, 25mg and 50mg administered once daily. After discontinuation of NBI-98854, a seven-day washout period was followed by a final assessment. The study inclusion criteria included a baseline total score of at least nine on the first seven components of the AIMS, with at least two body regions receiving scores of moderate (3) or severe (4). For this cohort of six subjects, the mean baseline score was 14.3 (AIMS total items 1-7, possible total score of 28).

After the twelve days of dosing in six subjects, the mean AIMS score decreased to 8.4, a reduction of 41.3%. Reduction in abnormal involunta
'/>"/>

SOURCE Neurocrine Biosciences, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. Neurocrine Biosciences to Present at the Cowen & Co. 31st Annual Health Care Conference
2. Neurocrine Biosciences Reports Fourth Quarter and Year End 2010 Results
3. Neurocrine Biosciences Announces Conference Call and Webcast to Report Third Quarter 2010 Financial Results
4. Abbott and Neurocrine Announce Global Agreement to Develop and Commercialize Elagolix for the Treatment of Endometriosis
5. Neurocrine Biosciences Announces Conference Call and Webcast on Worldwide Agreement With Abbott on Elagolix
6. Neurocrine Biosciences to Present at the Jefferies 2010 Global Life Sciences Conference and the 9th Annual Needham Healthcare Conference
7. Neurocrine Biosciences Announces Conference Call and Webcast to Present First Quarter 2010 Financial Results
8. Neurocrine Biosciences, Inc. Announces Exercise of Over-Allotment Option for Common Stock Offering
9. Neurocrine Biosciences to Present at the Roth 22nd Annual OC Growth Conference
10. Neurocrine Biosciences Announces the Appointment of William H. Rastetter to Its Board of Directors
11. Neurocrine Announces Top-Line Results From 703 Study (Tulip PETAL Study) of Elagolix for Treatment of Endometriosis Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... , July 30, 2014  Decision Resources ... and medical directors in the United ... of biosimilar market penetration will be the level ... (MCOs) and the expected lower cost to patients. ... biosimilars that meet their pricing expectations in order ...
(Date:7/30/2014)... 2014  Replikins Ltd. today released new data on ... Before the current outbreaks, the mean Ebola Reston gene ... between 1995 and 2002 was 1.1; the mean Replikin ... sixteen-fold in 2013, thus predicting the current outbreaks in ... been shown to be able to predict outbreaks (1). ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 Sales Horizons, ... launch of blended sales training programs for companies engaged ... training programs used by thousands of salespeople over 25 ... sales training program can be customized to address the ... The blended sales training program consists of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 July 30, ... @APDN), a biotechnology firm that provides DNA-based authentication and ... Hogan, Ph.D. Vice President of Life Sciences, a newly ... , Dr. Hogan will lead APDN’s drive to ... relationships with biotech and healthcare customers, provide guidance to ...
Breaking Biology Technology:Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 2Surveyed U.S. Payers Expect Cost Savings to MCOs and Patients to be the Strongest Drivers of Biosimilar Uptake 3Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 2Sales Horizons Launches New Blended Sales Training Programs to Companies Engaged in Complex B2B Sales 3Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 2Dr. Michael E. Hogan, Ph.D., Joins Applied DNA Sciences as Vice President, Life Sciences 3
... Ryan MILWAUKEE - Watts Wacker, hippie extraordinaire and rock-star ... birthday bash last week. I was floored by his ... notes. Here's what Watts offered, along with some R-squared ... 200 Christians. When Paulone of JC's disciplesfinally laid down, ...
... August, those seven days in which we attempt to pack all ... For me, this week also signals the calm before the storm. ... 2004. (Its a great lineup, so if you haven't grabbed your ... should be polishing my opening comments and prepping my introductions, but ...
... are millions of very expensive, well-designed websites all over ... offer with great graphic illustrations, supportive explanations about their ... in a very large majority of cases, what is ... people behind the site: the owners, the management the ...
Cached Biology Technology:Watts Up 2Wrapping up the Summer 2Wrapping up the Summer 3Wrapping up the Summer 4Whats Hush-Hush Marketing? 2Whats Hush-Hush Marketing? 3
(Date:7/31/2014)... as the Rim Fire was in full fury, raging ... it entered the backcountry of Yosemite National Park in ... the park, the battle began to turn, enacting a ... can combine to fuel large, severe fires. , "When ... lands where fire had been used as a management ...
(Date:7/31/2014)... with Hibiscus flowers- they are an iconic symbol ... planted in the landscape. Some, like Hawaii,s State ... , Only a relatively few botanists and Hawaiian ... beautiful and intriguing related group of plants known ... , Brother of Hibiscus species are in fact ...
(Date:7/31/2014)... White, brown and beige adipocytes, or fat cells, are ... functions and each plays its own role in metabolism. ... far the most prevalent. Its primary function is energy ... energy to generate heat but are only found in ... adipocytes, which represent a special type of brown adipocytes, ...
Breaking Biology News(10 mins):The Rim Fire 1 year later: A natural experiment in fire ecology and management 2The Rim Fire 1 year later: A natural experiment in fire ecology and management 3The Rim Fire 1 year later: A natural experiment in fire ecology and management 4The Rim Fire 1 year later: A natural experiment in fire ecology and management 5Brother of Hibiscus is found alive and well on Maui 2Hope for the overweight 2
... Edition: , , New hope for tapping vast domestic reserves ... to use in the U. S. , Toward a fast, ... proteins identified in the quest for male contraceptive, Toward more ... Resources: , Press releases, chat room sessions, and more ...
... The National Institutes of Health announced today that it ... NIH Director,s Pioneer and New Innovator Awards to 47 ... of their careers. The grants, estimated to be up ... pursue exceptionally innovative approaches that could transform biomedical and ...
... are thought to be involved in colon cancer but the ... have discovered that a molecule produced by a common gut ... The research, published in the October issue of the ... gut bacteria can cause colon cancer. There are more ...
Cached Biology News:ACS PressPac -- Sept. 17, 2008 2ACS PressPac -- Sept. 17, 2008 3ACS PressPac -- Sept. 17, 2008 4ACS PressPac -- Sept. 17, 2008 5ACS PressPac -- Sept. 17, 2008 6ACS PressPac -- Sept. 17, 2008 7ACS PressPac -- Sept. 17, 2008 8NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 2NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 3NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 4NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 5NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 6NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 7NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 8NIH extends commitment to transformative research with 2008 Pioneer, New Innovator Awards 9Cancer-causing gut bacteria exposed 2
Mouse polyclonal antibody to TNPO2 - transportin 2 (importin 3, karyopherin beta 2b)...
...
Mouse monoclonal antibody to ALAS2 - aminolevulinate, delta-, synthase 2 (sideroblastic/hypochromic anemia)...
... of an N-terminal FLAG® fusion and a ... from bicistronic mRNA. Two genes can ... transcription of a single message from the ... protein-protein interaction studies, multi-subunit proteins, and cloning ...
Biology Products: